Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biosynthesis of Nucleic Acids01:28

Biosynthesis of Nucleic Acids

478
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
478
Subviral Agents01:29

Subviral Agents

277
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
277
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

335
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
335
Prodrugs01:30

Prodrugs

3.5K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
3.5K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

4.6K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.6K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

48.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial.

The lancet. Gastroenterology & hepatology·2026
Same author

Annotated Bibliography of Prof. John A. Katzenellenbogen, PhD.

Journal of medicinal chemistry·2025
Same author

Celebrating John A. Katzenellenbogen, PhD and His Contributions to Science and Medicine.

Journal of medicinal chemistry·2025
Same author

Biological characterization of AB-343, a novel and potent SARS-CoV-2 M<sup>pro</sup> inhibitor with pan-coronavirus activity.

Antiviral research·2024
Same author

Structure-Activity Relationships and Discovery of (<i>S</i>)-5-(<i>tert</i>-Butyl)-11-(difluoromethoxy)-9-methoxy-2-oxo-1,2,5,6-tetrahydropyrido[2',1':2,3]imidazo[4,5-<i>h</i>]quinoline-3-carboxylic Acid (AB-161), a Novel Orally Available and Liver-Centric HBV RNA Destabilizer.

Journal of medicinal chemistry·2024
Same author

Rational Design of Macrocyclic Noncovalent Inhibitors of SARS-CoV-2 M<sup>pro</sup> from a DNA-Encoded Chemical Library Screening Hit That Demonstrate Potent Inhibition against Pan-Coronavirus Homologues and Nirmatrelvir-Resistant Variants.

Journal of medicinal chemistry·2024

Related Experiment Video

Updated: Nov 10, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.8K

Nucleotide prodrugs for HCV therapy.

Michael J Sofia1

  • 1Pharmasset, Inc., Princeton, NJ, USA. michael.sofia@pharmasset.com

Antiviral Chemistry & Chemotherapy
|August 24, 2011
PubMed
Summary

Nucleotide prodrugs show promise for treating Hepatitis C virus (HCV) infection. These agents effectively inhibit viral replication and reduce viral load in patients, offering a new therapeutic avenue.

Area of Science:

  • Hepatology
  • Virology
  • Medicinal Chemistry

Background:

  • Hepatitis C virus (HCV) infection is a global health concern and a leading cause of hepatocellular carcinoma.
  • Current treatments like interferon and ribavirin have limited efficacy in a significant portion of patients.
  • Direct-acting antiviral agents targeting viral replication are under development to overcome existing therapy limitations.

Purpose of the Study:

  • To review the development and efficacy of nucleotide prodrugs as direct-acting antiviral agents against HCV.
  • To highlight the strategy of using prodrugs to overcome limitations in nucleoside phosphorylation for HCV inhibition.
  • To survey the current state of nucleotide prodrugs in HCV treatment.

Main Methods:

  • Investigation of nucleoside analogs as inhibitors of HCV RNA-dependent RNA polymerase.

More Related Videos

Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides
08:46

Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides

Published on: July 26, 2018

8.9K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.5K

Related Experiment Videos

Last Updated: Nov 10, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.8K
Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides
08:46

Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides

Published on: July 26, 2018

8.9K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.5K
  • Development of nucleoside 5'-monophosphate prodrugs to enhance cellular delivery and intracellular phosphorylation.
  • In vitro and in vivo studies to assess the efficacy of these prodrugs in inhibiting HCV replication and reducing viral load.

    • Main Results:

    • Nucleoside prodrugs have been successfully developed to enable efficient delivery and intracellular activation to the triphosphate form.
    • Several nucleoside 5'-monophosphate prodrugs demonstrate potent inhibition of HCV replication in vitro.
    • Clinical trials show that these prodrugs significantly reduce viral load in HCV-infected patients.

    Conclusions:

    • Nucleotide prodrugs represent a promising therapeutic strategy for Hepatitis C virus infection.
    • Prodrug approaches effectively address the challenge of achieving intracellular active metabolites for polymerase inhibition.
    • The clinical progression of these agents indicates their potential to improve outcomes for HCV patients.